Genmab As Stock EBITDA

GMAB Stock  USD 21.55  0.28  1.28%   
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Stock. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS stock.
Last ReportedProjected for Next Year
EBITDA5.6 B5.8 B
The current year's EBITDA is expected to grow to about 5.8 B.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Genmab AS Company EBITDA Analysis

Genmab AS's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Genmab AS EBITDA

    
  5.56 B  
Most of Genmab AS's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Genmab EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Genmab AS is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as EBITDA. Since Genmab AS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab AS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab AS's interrelated accounts and indicators.
1.0-0.39-0.980.990.890.931.00.90.290.570.990.971.00.840.990.950.940.91
1.0-0.42-0.980.990.880.911.00.90.320.580.990.971.00.840.990.940.940.91
-0.39-0.420.28-0.38-0.25-0.06-0.38-0.23-0.89-0.33-0.47-0.44-0.42-0.46-0.3-0.32-0.31-0.26
-0.98-0.980.28-0.98-0.9-0.95-0.99-0.9-0.16-0.52-0.96-0.93-0.98-0.82-0.99-0.94-0.94-0.95
0.990.99-0.38-0.980.90.910.990.890.230.460.970.960.980.80.990.940.930.92
0.890.88-0.25-0.90.90.880.90.830.050.380.850.890.870.650.910.820.820.9
0.930.91-0.06-0.950.910.880.930.860.00.460.880.880.910.730.950.890.890.91
1.01.0-0.38-0.990.990.90.930.90.270.570.990.971.00.830.990.950.940.92
0.90.9-0.23-0.90.890.830.860.90.140.50.880.890.90.720.90.850.850.84
0.290.32-0.89-0.160.230.050.00.270.140.450.390.320.320.40.180.210.190.12
0.570.58-0.33-0.520.460.380.460.570.50.450.640.560.580.660.510.60.590.51
0.990.99-0.47-0.960.970.850.880.990.880.390.640.980.990.850.970.930.930.87
0.970.97-0.44-0.930.960.890.880.970.890.320.560.980.980.840.960.940.940.85
1.01.0-0.42-0.980.980.870.911.00.90.320.580.990.980.840.980.940.940.9
0.840.84-0.46-0.820.80.650.730.830.720.40.660.850.840.840.810.930.920.79
0.990.99-0.3-0.990.990.910.950.990.90.180.510.970.960.980.810.950.950.92
0.950.94-0.32-0.940.940.820.890.950.850.210.60.930.940.940.930.951.00.89
0.940.94-0.31-0.940.930.820.890.940.850.190.590.930.940.940.920.951.00.89
0.910.91-0.26-0.950.920.90.910.920.840.120.510.870.850.90.790.920.890.89
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

Genmab Ebitda

Ebitda

5.84 Billion

At present, Genmab AS's EBITDA is projected to increase significantly based on the last few years of reporting.
According to the company disclosure, Genmab AS reported earnings before interest,tax, depreciation and amortization of 5.56 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 42.64% lower than that of the firm.

Genmab EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.
Genmab AS is currently under evaluation in ebitda category among its peers.

Genmab AS ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab AS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab AS's managers, analysts, and investors.
Environmental
Governance
Social

Genmab AS Institutional Holders

Institutional Holdings refers to the ownership stake in Genmab AS that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Genmab AS's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Genmab AS's value.
Shares
Envestnet Asset Management Inc2024-09-30
M
Goldman Sachs Group Inc2024-09-30
825.1 K
Royal Bank Of Canada2024-09-30
797.8 K
Two Sigma Investments Llc2024-09-30
767.9 K
Wells Fargo & Co2024-09-30
700.4 K
Two Sigma Advisers, Llc2024-09-30
615.1 K
Ddd Partners, Llc2024-09-30
583.1 K
Millennium Management Llc2024-09-30
564.8 K
Voloridge Investment Management, Llc2024-09-30
548.4 K
Alliancebernstein L.p.2024-09-30
15.1 M
Blackrock Inc2024-06-30
5.1 M

Genmab Fundamentals

About Genmab AS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Genmab AS Piotroski F Score and Genmab AS Altman Z Score analysis.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.38)
Earnings Share
1.02
Revenue Per Share
30.6997
Quarterly Revenue Growth
0.176
Return On Assets
0.1095
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.